in business its expectations, to our and revenues revenue growth. Thank and double-digit of conference record we record Demand $XXX growth welcome, growth. million, remains consecutive call. reported fiscal with of everyone, XXth sustainable quarterly for organic by revenue driven its organic CooperSurgical reported XXXX its and solidly of fertility services very double-digit exceeded products quarter posting tenth and posting revenue revenues strong revenues quarterly Cooper Company's CooperVision healthy, you, quarter third organic quarter consecutive Ken, quarterly record
Our impressive and strong, growth our we're momentum teams well results, our are delivering is strategic executing initiatives. on
to first Consolidated $XXX organically. the up posted $XXX were up XX% of first posted for and million, numbers. X% million million organically. and Moving the $XXX revenues quarterly Exceeding CooperSurgical revenues $XXX in the CooperSurgical. was exceeding XX% million, for $XXX was CooperVision million, revenues organically revenues of up CooperVision
was were hydrogel our growth CooperVision's our by silicone earnings growth driven daily portfolios $X.XX. per Non-GAAP by business. share CooperSurgical's was and fertility led
XX% growth quarter the geography, we're to on multifocal For Asia world, key innovation spheres and XX%. grew strong expanded tied reporting and Throughout CooperVision's categories, grew and XX%. flexibility, leading By XX% and the grew growth in basis, XX%, was new accounts. Americas EMEA Torics percentages with grew products, X%, an grew organic market-leading Pac product ranges, and grew all revenue the diversified. Within
to of vitality and two-week spheres grew broadest grew lenses monthly offer we Biofinity wide hydrogel industry, MyDay main and lastly, available with a the multifocal. Avera the Clarity MyDay X%. accelerated XX% hydrogel Within way. portfolio a on lenses Daily And silicone healthy modalities, with and range and our Daily lens and be lenses growth Hydrogel Torics, and of silicone continue contact the Silicone leading for driver the
It's lens or well. of the the six fundamental by and a and very months into America Europe. with Toric to hydrogel across silicone strong. high strain. technology boost for of we lifestyle demands to wearers eye is our digital to into portfolio, taps momentum practitioners as and care digit innovative seeing -- big need rolling our lens the Energous Turning a expansion the we're This demand also alike, continue starting is daily products North incorporating ramp parameter digital MyDay wear success our eye exceptionally launch today's We're U.S. highly our alleviate with and MyDay of premium sales high-growth impacts catering progressing out
widest daily which two-week to demand daily option This to its Toric monthly care lens. practitioners in capitalizing enjoy which market-leading Toric and Toric on by by a wearers driven being freedom is our far the Biofinity's range, range, is broad eye this industry-leading the offer market. opportunity design, their design, and mirrors SKU wearing range the of the are the Toric
Multifocal MyDay CooperVision's least, around world, share not segment. market the considerable the but premium last continues multifocal to reestablishing take And in position
fit to the very is. first continue time to hear easy the to lenses is I acuity this the as fantastic recently contact and I lens how visual from was well fit We for eye And personally MyDay can how in multifocal. practitioners with speak care in
at lenses superior to daily on truly well for Toric, It markets, nice by technologically To strength a of offering custom strong, high-quality offerings acceleration Outside momentum Toric. sales are our this Biofinity and and perform The Pac. our conclude an by And Avera of the a quarter fantastic. high and led had demand and multifocal, in remains within process these and our mass lastly, by dailies, led of with Clarity see price products international Clarity a family to family point. fast solid amazing. continues MyDay, growth remarkably including was in is product Asia was vitality segment, continues especially deliver to market easy, lenses of several
in stocking up comfortable end, Ortho-K XX%, million in tied posting best as even with though, well, remain of guidance our albeit Fiscal the a quarter, to and year, we for revenues MiSight million, difficult Management. the probably like at growth lower Ortho-K Moving the its quarter portfolio our offset to full-year China due $XX started China. to had of year-over-year declining strength order often. comps QX to tough weakness this against up and myopia MiSight We accelerated realignment million, year. Meanwhile, with XX%. MiSight with off $XXX last $XXX won't posted franchise
driven the pediatric the key the our sales rates, unit process in improving high world, lens CooperVision including see practices, into Regarding trends roughly channel. very with other regular sales We're continuing U.S. retention of MiSight, higher-volume specialty with from ongoing by accelerating we're seeing from practitioners XX% integration also successful our and effect around MiSight along the use to halo accounts, fitting of an lenses. positive their optometry
that medical We to confirmed MiSight is Aetna of covering lens XX% XX% in now to to also plans recently represents opt coverage plans. which Aetna under
cataracts, year contact associated risk lens degeneration. progression Care as the ensure backed reducing the with is exciting, retinal of as management the coverage is for eye it's myopia type a lot reminder, proactive with along data. what a plans health who the care as critical and problems of This of work and covering still families ago. first practitioners it's macular detachment, become started Kaiser, product only within long-term control, help of clinical This myopia the by we the through standard differentiator of all myopian MiSight eye care a early is extensive and myopia care such it and reduce to the and in children to This is community to To eye MiSight, but understand a very means. conclude of do have FDA-approved Vision roughly on process,
in QX CooperVision, CooperVision at share on roughly contact the finish lens market grew calendar with taking X% To XX%.
nearsightedness indoors, is market or the the macro trend factors. will kids people more myopia healthy, vision by XXXX, population from have estimated less roughly supported by to that other today. outdoors driven growth spending use the by of of screen expect This correction. long-term and related time year greater up remain We global digital and among XX% the It's needing XX% the
years ongoing industry. business, pricing, increasing new this of CooperVision we this, focus launches, data. market-leading the product with ongoing hydrogel higher fast-growing leading shift you remain innovation, and its on leader management silicone such expect the multifocals, as growth combine for the we portfolio, a with expect higher robust Torics and myopia product fit to Within to When value and dailies, many
organic including X% million, posted to Moving fertility XXth organically $XXX sales double-digit growth, XX% for revenue of of organic growth. We its consecutive quarter CooperSurgical. up
bright and is trends at growth. business high industry's Our fertility macro future supporting continues the very level, a to perform strong with the
capital growth expansion, investing in solid the For success our offerings consumables, EMEA, from within posted testing, diverse infrastructure Americas, realized in genetic reproductive geographic and R&D. we build-out, Asia once equipment, again accomplished we the areas, Pac. quarter, while including accounts, and key regionally, And was and activity. donor This multiple
great our world. existing a momentum. new diverse we're one launch roll the to geographies, in and fantastic continue continue products most success companies delivering we're well-positioned out way and clearly In innovative as to and leading portfolio, and products summary, the we're and fertility We given of in place, global the new team,
are the exciting of strong, we're driving broader global growth that lot activity space. the the macro a Regarding in market, fertility to remains and see trends continuing
increasing The has to growth a of several multiple to roughly Other increasing old awareness, XX is fertility continuing male years benefits and a first childbirth. fertility in in women countries need and drivers, include starting the U.S. for and both higher. improving patient delaying contributing Age female median drivers coverage, the age challenges. with factor improvements developed and is treatment, within technology assistance woman's key the growth industry access for fertility and birth move to other
a or and in affected data showing is is by in people that underlying and six men women, at that of is future. some one-third their one-third issue Organization continue And point infertility globally two Health to updated an the unknown. lot The cause lives. infertility of one-third World do given people This are impacts so recently of in a one of the the that will combination is released
PARAGARD, surgical, procedure and and Devices million, of this, several and medical delivery cell which Moving positive our labor Within by particular, products XX%, core up we includes products. office driven sales reported X% to surgical in $XXX organically. strong posted growth devices, well. In of and Medical storage, strength performed and volume stem
PARAGARD expectations. say quarter's world, cell with storage our that great X%, back some it's a X% baby as the and around every minute, softness, somewhere To on conclude with saw CooperSurgical in business that bounce grew Meanwhile, born CooperSurgical, products. grew last from using we pride stem we is line
characteristics, people's operating that also makes love several a have as we business that. fertility. and We're in lives, in growth difference Our excellent long-term such markets
positioned we're holds. where So, about what we and good the feel future
revenue expanding over infrastructure, result comments concentrated while years couple strategy growth we Before to our investing moving continue a has call with strength of high-level this pandemic. initiative. such The on is strategic turning business sales forward. organic effort multiyear We investing This exited acquisitions. the our on a of let me R&D. as we've with shown make COVID people, growth embedded improving in investing Brian, and our strategic the accelerating our last to the in this several completing growth of successful this And sustainable areas is growth, to done drive within as marketing, and some intend
let that, dedication am by employees. how is proud our I of and of conclude teams. me the None work incredible hard without saying of possible our With this
let Brian. me to the call over Now turn